Topic: cardiovascular disease
Idorsia spun out of Actelion before it was taken over by J&J earlier this year, but it will still play a big part in one of its lead products.
The Big Pharma reached the decision after going over a mixed set of data from its big bet on a phase 3 program.
Moderna looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.
Akcea sees the filing positioning it to bring the treatment of familial chylomicronemia syndrome to market in the U.S. next year.
The Philips-HeartFlow deal follows earlier agreements with GE Healthcare and Siemens Healthineers.
Novartis is paying $31 million upfront for gevokizumab, a price that reflects the battering its prospects took as a development program unraveled.
The past week brought new discoveries related to opioid addiction, heart failure and inflammation.
The past week ushered in discoveries related to the genetics of immuno-oncology success, genes and heart failure, and treating Gulf War illness.
MyoKardia just announced that its experimental drug mavacamten improved heart function in patients with an inherited cardiac condition.
Researchers have uncovered clues into how a genetic variant raises the risk of migraines, coronary artery disease and other related disorders.